Cargando…

Outcomes in Ethnic Minority Renal Transplant Recipients Receiving Everolimus versus Mycophenolate: Comparative Risk Assessment Results From a Pooled Analysis

BACKGROUND: Everolimus (EVR) has demonstrated good efficacy after renal transplantation. Racial disparities in clinical outcomes after de novo renal transplantation are well documented; whether the efficacy of EVR varies based on recipient ethnicity is unknown. We conducted a comparative risk assess...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melancon, Keith, Mulgaonkar, Shamkant P., Delcoro, Carlos, Wiland, Anne, McCague, Kevin, Shihab, Fuad S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2013
Materias:	Clinical and Translational Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888463/ https://www.ncbi.nlm.nih.gov/pubmed/24345868 http://dx.doi.org/10.1097/TP.0b013e3182a486f5

Ejemplares similares

Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus
por: Shihab, F., et al.
Publicado: (2017)

Association of mycophenolic acid dose with efficacy and safety events in kidney transplant patients receiving tacrolimus: an analysis of the Mycophenolic acid Observational REnal transplant registry
por: Doria, Cataldo, et al.
Publicado: (2012)

Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients
por: Brunkhorst, Lena Caroline, et al.
Publicado: (2015)

Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study
por: Charlton, Michael, et al.
Publicado: (2017)

Everolimus/mycophenolate-mofetil: COVID-19 pneumonia: case report
Publicado: (2021)

Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy
por: Hwang, Shin, et al.
Publicado: (2017)

Stepwise Reduction of Mycophenolate Mofetil with Conversion to Everolimus for the Treatment of Active BKV in Kidney Transplant Recipients: A Single-Center Experience in Vietnam
por: Kien, Truong Quy, et al.
Publicado: (2022)

Utilization of Mycophenolic Acid, Azathioprine, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus: Multinational Study
por: Sahman, Majda, et al.
Publicado: (2021)

Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms
por: Pithukpakorn, Manop, et al.
Publicado: (2014)

Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium
por: Jia, Yichen, et al.
Publicado: (2017)

Does reduction in mycophenolic acid dose compromise efficacy regardless of tacrolimus exposure level? An analysis of prospective data from the Mycophenolic Renal Transplant (MORE) Registry
por: Langone, Anthony, et al.
Publicado: (2013)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study
por: Noreikaitė, Aurelija, et al.
Publicado: (2017)

Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
por: de Boer, Silke E., et al.
Publicado: (2022)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
por: Santos, C D, et al.
Publicado: (2015)

Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and translational trials
por: Ormanns, Steffen, et al.
Publicado: (2016)

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
por: Cejka, D, et al.
Publicado: (2009)

Everolimus with or without mycophenolate mofetil in a liver transplantation setting: a single-center experience
por: Cholongitas, Εvangelos, et al.
Publicado: (2018)

Muriatic acid ingestion complicated by penetrating head injury: A case report and literature review
por: Shub, Eric, et al.
Publicado: (2016)

Recreational Drugs and Outcomes in Trauma Patients
por: Fujii, Quinn, et al.
Publicado: (2019)

Spontaneous Bladder Rupture After Binge Drinking
por: Miller, Jeremy, et al.
Publicado: (2023)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
por: Damiano, V, et al.
Publicado: (2013)

Everolimus Rescues the Phenotype of Elastin Insufficiency in Patient Induced Pluripotent Stem Cell–Derived Vascular Smooth Muscle Cells
por: Kinnear, Caroline, et al.
Publicado: (2020)

Impact of SLCO1B3 Polymorphisms on Clinical Outcomes in Lung Allograft Recipients Receiving Mycophenolic Acid
por: Tague, Laneshia K., et al.
Publicado: (2019)

Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil
por: Traitanon, Opas, et al.
Publicado: (2019)

The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients
por: AbdElhalim, Mohamed S., et al.
Publicado: (2020)

From the bench to the bedside: Everolimus for subependymal giant cell astrocytomas in Tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas
por: Hauptman, Jason S.
Publicado: (2011)

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma
por: Voss, Martin H, et al.
Publicado: (2016)

Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
por: Vandamme, Timon, et al.
Publicado: (2016)

Everolimus induced pneumonitis in a lung transplant recipient
por: Arunachalam, Ambalavanan, et al.
Publicado: (2018)

Effect of Mycophenolate Mofetil on Plasma Bioelements in Renal Transplant Recipients
por: Kamińska, Jolanta, et al.
Publicado: (2011)

Hemorrhagic Cholecystitis after Warfarin Use for Deep Vein Thrombosis
por: Donn, Eric, et al.
Publicado: (2018)

Empiric Stress Dose Steroids in Trauma Patients: A Case Report of Hypopituitarism in Traumatic Hemorrhage
por: Haberlach, Marissa, et al.
Publicado: (2019)

Marijuana Screening and Trauma Outcomes
por: Fujii, Quinn, et al.
Publicado: (2020)

Management of Complex Duodenal Injuries After Penetrating Trauma
por: McCague, Andrew, et al.
Publicado: (2023)

Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients
por: Zhang, Jun, et al.
Publicado: (2017)

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(−) advanced breast cancer: results from BOLERO-2
por: Moynahan, Mary Ellen, et al.
Publicado: (2017)

Converting everolimus to mycophenolate mofetil ameliorated prolonged respiratory syncytial virus infection in a child after heart transplantation
por: Suginobe, Hidehiro, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mj7oi88e64666cibkos3v420dh